StockData
HCW Biologics Inc. logo

HCW Biologics Inc. (HCWB) stock

HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.75+0.01 (+1.90%)

Close on Nov 20, 2026Market cap $1.38MP/E –Yield –

HCW Biologics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

HCW Biologics's operating income for the twelve months ending Jun 30, 2026 was -$7.68M. For fiscal 2025 it was -$13.16M. The highest annual figure on record is -$5.82M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.16M–
FY2024Dec 31, 2024-$29.46M–
FY2023Dec 31, 2023-$25.72M–
FY2022Dec 31, 2022-$15.08M–
FY2021Dec 31, 2021-$13.37M–
FY2020Dec 31, 2020-$5.82M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.17M–
Q1 FY2026Mar 31, 2026$3.24M–
Q4 FY2025Dec 31, 2025-$4.46M–
Q3 FY2025Sep 30, 2025-$3.29M–
Q2 FY2025Jun 30, 2025-$3.46M–
Q1 FY2025Mar 31, 2025-$1.97M–
Q4 FY2024Dec 31, 2024-$3.15M–
Q3 FY2024Sep 30, 2024-$3.68M–
Q2 FY2024Jun 30, 2024-$15.14M–
Q1 FY2024Mar 31, 2024-$7.49M–
Q4 FY2023Dec 31, 2023-$10.77M–
Q3 FY2023Sep 30, 2023-$5.08M–
Q2 FY2023Jun 30, 2023-$4.51M–
Q1 FY2023Mar 31, 2023-$5.36M–
Q4 FY2022Dec 31, 2022-$5.67M–
Q3 FY2022Sep 30, 2022-$4.02M–
Q2 FY2022Jun 30, 2022-$3.51M–
Q1 FY2022Mar 31, 2022-$1.88M–
Q4 FY2021Dec 31, 2021-$3.11M-251.0%
Q3 FY2021Sep 30, 2021-$4.09M–
Q2 FY2021Jun 30, 2021-$2.75M–
Q1 FY2021Mar 31, 2021-$3.41M–
Q4 FY2020Dec 31, 2020$2.06M–
Q3 FY2020Sep 30, 2020-$2.71M–
Q2 FY2020Jun 30, 2020-$2.78M–

More HCW Biologics figures

See a number that looks wrong?